| abstract |
The present invention generally relates to the desing, expression and purification of truncated forms of the human dbf4 protein, optionally in complexe with dbf4 interacting partners, such as human cdc7, and its use in the discovery, indentification and characterization of inhibitors of the components of the complex, either when associated or when present as uncomplexed proteins in situ or in vitro. More specifically, the present invention relates to the utilization of specific truncated forms of human dbf4 for the production of an active, non-aggregated, monodispersed hetorodimer of human dbf4 complexed to human cdc7, or other protein interactors. |